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Abstract
Background: Alterations of chromosome 8 and hypomethylation of LINE-1 retrotransposons are common alterations
in advanced prostate carcinoma. In a former study including many metastatic cases, they strongly correlated with each
other. To elucidate a possible interaction between the two alterations, we investigated their relationship in less advanced
prostate cancers.
Results: In 50 primary tumor tissues, no correlation was observed between chromosome 8 alterations determined by
comparative genomic hybridization and LINE-1 hypomethylation measured by Southern blot hybridization. The
discrepancy towards the former study, which had been dominated by advanced stage cases, suggests that both alterations
converge and interact during prostate cancer progression. Therefore, interaction analysis was performed on microarray-
based expression profiles of cancers harboring both alterations, only one, or none. Application of a novel bioinformatic
method identified Gene Ontology (GO) groups related to innate immunity, cytoskeletal organization and cell adhesion
as common targets of both alterations. Many genes targeted by their interaction were involved in type I and II interferon
signaling and several were functionally related to hereditary prostate cancer genes. In addition, the interaction appeared
to influence a switch in the expression pattern of EPB41L genes encoding 4.1 cytoskeleton proteins. Real-time RT-PCR
revealed GADD45A, MX1, EPB41L3/DAL1, and FBLN1 as generally downregulated in prostate cancer, whereas HOXB13
and EPB41L4B were upregulated. TLR3 was downregulated in a subset of the cases and associated with recurrence.
Downregulation of EPB41L3, but not of GADD45A, was associated with promoter hypermethylation, which was detected
in 79% of carcinoma samples.
Conclusion: Alterations of chromosome 8 and DNA hypomethylation in prostate cancer probably do not cause each
other, but converge during progression. The present analysis implicates their interaction in innate immune response
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suppression and cytoskeletal changes during prostate cancer progression. The study thus highlights novel mechanisms in
prostate cancer progression and identifies novel candidate genes for diagnostic and therapeutic purposes. In particular,
TLR3 expression might be useful for prostate cancer prognosis and EPB41L3 hypermethylation for its detection.
Background
Up to 40% of all elderly men may harbor prostate carci-
nomas, less than 20% develop symptomatic disease,
which in about 3% becomes the cause of death. Great
advances have been made in prostate cancer detection due
to refined PSA-based assays, imaging and histopathology.
In their wake, two questions have gained importance, i.e.
which tumors represent clinically significant disease and
how tumors having progressed locally or metastasized can
be identified and appropriately treated. Molecular
research is thus challenged to provide a reliable classifica-
tion of prostate cancers and to identify targets for novel
therapies in those tumors no longer containable by sur-
gery, irradiation, and anti-androgenic therapy.
Among such aggressive prostate cancers, molecular altera-
tions are not uniform. Instead, these tumors contain dif-
ferent combinations of genetic and epigenetic aberrations
that each appear to influence the biological processes cru-
cial for the cancer phenotype [1-3]. It is therefore neces-
sary to disentangle the influence of individual alterations
by factor analysis approaches. Through defining the bio-
logical consequences of particular recurrent molecular
alterations – considered as factors – it may become possi-
ble to identify subgroups of prostate carcinoma whose
behavior is determined by them. These factors could then
be used to predict the prognosis in each particular sub-
group. In addition, elucidation of the mechanisms by
which a factor exerts its effects on prostate cancer progres-
sion would provide specific targets for therapy within the
respective subgroup. This approach does not imply that
factors act independently of each other. Indeed, we sug-
gest here that two molecular alterations previously identi-
fied as being associated with more aggressive prostate
cancers appear to interact in a synergistic fashion during
tumor progression.
The first factor, alteration of chromosome 8, is found in
up to 50% of prostate cancers [1-3]. A large number of
publications have concordantly reported that chromo-
some 8 alterations are significantly associated with vari-
ous established histopathological indicators of poor
prognosis or directly with clinical outcome. Curiously, 8p
losses or 8q gains both seem to have similar clinical effects
(reviewed in [4]). One reason for this unusual relation-
ship is that 8q gain is often mechanistically linked to 8p
loss through isochromosome 8q formation [5]. Moreover,
it has been difficult to trace the effect of chromosome 8
alterations to any single gene [2]. Interestingly, chromo-
some 8 has also emerged as the site of a hereditary pros-
tate cancer gene in genome-wide searches. A good
candidate is MSR1 at 8p23.1. Inherited mutations at this
locus are presumed to modify immune responses during
carcinogenesis [1]. Thus, the importance of chromosome
8 alterations as a factor in prostate cancer progression is
undisputed, but the question of which biological proc-
esses they influence is open.
The second factor is hypomethylation of LINE-1 retro-
transposons, which constitute approximately 18% of the
human genome. LINE-1 hypomethylation is part of a
broader process, 'genome-wide' hypomethylation that
affects not only repeat sequences, but also single-copy
genes inactivated by DNA methylation in normal adult
tissues [6]. While hypomethylation occurs at early stages
in some cancer types, it is associated with tumor progres-
sion in others. Conceivably, this association is brought
about by increased chromosomal instability as a conse-
quence of repetitive sequence hypomethylation and by
reactivation of specific genes favoring tumor cell survival
and adaptation during invasion and metastasis [7]. How-
ever, the details of the relationship between genome-wide
hypomethylation and cancer progression are poorly
understood. In prostate cancer, LINE-1 hypomethylation
is detected in only a subset of localized cancers, but is
highly prevalent in high-stage and metastatic cases [8,9].
In contrast, hypermethylation of selected single copy
genes occurs consistently at early stages of carcinogenesis
[9,10].
The two factors, chromosome 8 alterations and LINE-1
hypomethylation, may not be independent of each other.
In a previous study of 55 prostate carcinomas including
many advanced stage and recurrent cases, we found LINE-
1 hypomethylation to be highly significantly associated
with chromosomal instability [8], in keeping with expec-
tations from other cancer types and animal models [6,7].
Unexpectedly, we found a particularly close relationship
between hypomethylation and chromosome 8 altera-
tions. This raised the question whether this association
was (i) mechanistic, i.e. a consequence of chromosome 8
destabilization by hypomethylation or, conversely, dereg-
ulation of DNA methylation as a consequence of chromo-
some 8 changes, (ii) the consequence of a common factor
causing both alterations, or (iii) an indication of a func-
tional interaction between both factors that promotes
prostate cancer progression. Here, we will present evi-
dence that explanation (iii) is most likely. Our analysisMolecular Cancer 2007, 6:14 http://www.molecular-cancer.com/content/6/1/14
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revealed that the interaction of the two factors appears to
relate to several biological processes already implicated in
prostate cancer progression, prominently suppression of
immune responses and changes in the cortical actin
cytoskeleton and the extracellular matrix.
Results
Comparative genomic hybridization and DNA methylation 
analysis
Our previous study had revealed a highly significant asso-
ciation between LINE-1 hypomethylation and chromo-
some 8 alterations, particularly in tumors with distant
metastases or recurring after anti-androgenic therapy [8].
To further elucidate this association, we investigated
whether it also existed in less advanced cancers. From a
previous study of DNA methylation alterations in prostate
carcinoma [9], a subset of 50 primary tumors without dis-
tant metastases were selected by the criteria of availability
of high-quality DNA and RNA and complete follow-up
data (Table 1). Almost all tumor tissues presented hyper-
methylation in several genes typically hypermethylated in
prostate cancer (Table 1).
For all cases, comparative genomic hybridization (CGH)
analysis was performed using the same DNA aliquots
employed in methylation analysis (Table 1). Overall, 17
tumors revealed typical changes in chromosome 8 dosage.
Loss of 8p was detected in 6 cases and gain of 8q in 13
cases. Three tumors exhibiting nontypical 8p gain or 8q
loss were not categorized as 'chromosome 8 altered'.
Significant LINE-1 hypomethylation (>4%) was found in
17 tumor specimens (Table 1). Only five of these har-
bored 8p losses or 8q gains, 12 tumors each contained
either hypomethylation or chromosome 8 alterations,
and in 21 cases neither alteration was detected. Thus, in
the present series no association was found between
LINE-1 hypomethylation and chromosome 8 alterations.
The previously measured association therefore likely
reflects a convergence in late stage prostate cancers, i.e.
both molecular alterations may be selected for during pro-
gression of prostate cancers towards an aggressive pheno-
type. This co-selection is most straightforwardly explained
by a synergistic influence of the two factors on biological
processes important for tumor progression.
Microarray expression analysis
To identify which biological processes might be targeted
by the supposed synergism, expression profiling was per-
formed. From those cases for which ample high quality
RNA was available, 24 tumors were selected exhibiting
only chromosome 8 alterations (8p loss, 8q gain, or
both), only LINE-1 hypomethylation, chromosome 8
alterations as well as LINE-1 hypomethylation ('both'
group), or neither alteration (Table 1). The specimens
lacking both changes were selected to harbor a maximum
of other chromosomal alterations. Total RNA from each
case was hybridized to Affymetrix U133A oligonucleotide
arrays, without pre-amplification.
This experimental setup allows three comparisons, i.e. (i)
cancers with or without chromosome 8 alterations, (ii)
cancers with or without LINE-1 hypomethylation, and
(iii) an interaction analysis of both factors. In the interac-
tion analysis, we considered those genes as significant,
whose changes in expression were significantly greater in
'both' cancers than the sum of the changes in cancers with
one alteration, each compared to the cancers without
either alteration (see Methods). Moreover, since we were
interested in the identification of biological processes tar-
geted by the presumed interaction, all comparisons were
performed for Gene Ontology (GO) 'biological process'
groups (see Methods). In this analysis, a Gene Ontology
group is highlighted if it is enriched, i.e. if it contains sta-
tistically significantly more differentially expressed genes
than expected by chance.
Intriguingly, few differences were discovered in the com-
parisons based upon differential methylation or upon the
presence of chromosome 8 alterations (Figure 1A). In
contrast, the interaction analysis revealed a number of
highly significant differences (Figure 1A). Initially, the
classic algorithm (see Methods) for testing enrichment was
used. The majority of the significant terms obtained with
this algorithm were related to 'immune response' and
'response towards wounding' (areas 1. and 2. in Figure
1B). A prominent unrelated GO group was #30865 (area
7. in Figure 1B). Individual genes significant within GO
groups are listed in Additional file 1 (further information
on Figures 1B and 1C can be found in Additional file 3).
Expression of immune response-related genes
Several genes individually significant in the interaction
analysis were selected for closer analysis. The microarray
results for these and some related other genes are shown
in Figure 2. Figure 3 presents a comparison of their expres-
sion analyzed by quantitative RT-PCR in 47 cancer sam-
ples (including almost all used in the microarray analysis)
and 13 morphologically normal prostate tissues obtained
from distant sites of cancer-carrying prostates. This latter
analysis allows to determine whether these genes were dif-
ferentially expressed not only among prostate cancer
groups, but also between prostate cancers and noncancer-
ous tissue in general. As a quality control, HPN (Hepsin)
expression was first determined in all these samples and
was strongly increased in cancerous over benign tissues
(Figure 3A), as expected [14-17]. As another quality con-
trol, DNA from the benign tissues used exhibited neither
GSTP1 nor RARB2 hypermethylation, excluding contami-
nation with tumor [9,10].Molecular Cancer 2007, 6:14 http://www.molecular-cancer.com/content/6/1/14
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Table 1: Clinical, methylation and CGH data for prostate cancer tissues
Tumor No. Stage Gleason Score Molecular Group LINE-1 %hypo No. hypem. genes Chromosomal losses Chromosomal gains
36 pT3bN0 7 1 4 - 3q21q26.2
38 pT2N0 7 4 4 - -
50 pT3bN0 7 hypo 10 4 1q31 6p,7p,16p,17p, 18p,19, 
20q13,21,22,Y
65 pT3bN0 7 both 9 4 Y 1p33p34.3, 2p21p23, 2q14.1q14.3, 
2q33q36, 3p14.1p21.3, 
3q25.1q26.3, 4q13.3q28, 5q22, 
5q31.2q32, 6q16.1q22.1, 
8q22.1q23, 10p11.2p13, 
10q11.2q22.3, 12q13.2q24.31, 
13q21.1q31, 14q21q32.2, 
18q11.2q22, Xp21.3q27
83 pT3bN0 7 hypo 6 4 1q31, 2q33q37, 4q31, 13q21q31, 
15q24,
4q12, 5q13, 17p, 18p, 19, Y
89 pT2bN0 3 hypo 5 2 9q33q34, X 2q11q24, 4q12q22, 6q22, 12p,18p, 
Y
93 pT3bN0 7 4 4 - Yq
95 pT3bN1 10 hypo 7 4 Xq 18p, Y
99 pT2bN0 5 0 1 - 2q14q24,10q11q21
101 pT3aN0 8 none 0 3 1p36, 14q31q32, 17p, 22 -
105 pT3aN0 5 1 1 1p36,2,3,4 -
107 pT3aN0 7 none 3 4 18p, Y 4q24, 6q22, Xp11.2p11.4
117 pT3bN0 5 3 4 - 1q21q25,2q11q14,19q13
119 pT3bN1 9 none 1 3 7p15pter, 15q23qter, Y 10q21q22
121 pT2bN0 6 chrom8 1 4 1q32q41, 3p21, 4p15p16, 
8p22p23, 9p23p24,10q25q26, 
11q23q25, 12q24, 13q32q34, 
14q24q32, 15q24q26, 17q24q25, 
Xp21p22
Yq
123 pT2aN0 5 1 1 9q21.2q21.3, 10q26, 16p, Y 2p14p16, 2q24.3q32.1, 6q14q16.1
125 pT2bN0 6 1 0 14q31 -
127 pT2bN0 7 none 2 2 7q36, Yq 2q22q32.3, 4q11q31.3, 
13q14.1q21.1, 14q21q23, 
15q21.1q23
133 pT2bN1 7 chrom8 0 4 22, Y 1q, 2q22q34, 3q11.1q26.1, 
4q22q27, 5q21q31, 6q21q24, 
8q11q23, 10q11q21.3, 12q21q22, 
14q12q22, X
137 pT2bN0 8 chrom8 1 1 16, 17, 18p, 18q11.1q21.1, 19, 
21q22, Y
3q23q26.3, 4q13.2q21.3, 5q, 
7q13q31, 8p21pter, 8q24, 9p, 
14q13qter
139 pT3bN1 9 chrom8 1 4 19q, Y 1q25q31, 2q11q33, 3, 4q, 
5q13q23, 6q14q25, 7q21qter, 
8q13q23, 11q14qter, 13q21q32, 
14q11.1q21, 18q12, Xq21.3qter
141 pT2bN0 4 chrom8 0 2 16, 17, 18p, 19, 20, 22, Y 1q31q32.1, 2, 3q13.3qter, 
4q11q31.1, 5q14qter, 6q, 
7p12pter, 7q22q31.2, 8q12q21.2, 
10q21.1q23.1, 11q14.3qter, 
12q14qter, 13q14.1qter
145 pT4N1 7 hypo 11 3 Y 3q25q27,4q24q26,7q11q22,13q31
q34,17p,18p
149 pT2bN0 6 2 2 Y 2p, 4p12, 4q24q26, 5q11q13, 
7p12, 8q23q24, 9,11q22, 
12q12q15, 14q24, 17, 19, 20q13,Molecular Cancer 2007, 6:14 http://www.molecular-cancer.com/content/6/1/14
Page 5 of 16
(page number not for citation purposes)
151 pT3aN0 7 0 1 3p13p14 6p14, Xp21
153 pT3aN0 5 2 1 Xq11.2q13
155 pT3aN0 5 5 4 19p 3p25p26, Y
157 pT2aN0 8 2 0 - 1q21q31, 2q12q24, 3q, 4q12q21, 
5q13q14, 6q14q16, 7q11, 
8q12q22, 12q12q13, 18p, Y
161 pT2bN0 5 3 4 15q22q24, Xq22q25 -
163 pT3bN1 5 chrom8 2 2 16, 17p, 18p, 20, Y 1q25qter, 2p11p16, 2q32q34, 
3q12, 3q21q27, 4q, 6q15q24, 
8q12q21, 8q23q24, 12q13q21, 
13q14q32, 14q12q21, 18q, 
Xq11.1q26
169 pT3aN0 7 chrom8 3 2 16, 17p, 18p, 19, Y 2, 3, 4q, 5q, 7p15pter, 8q22q24, 
13q31qter, 14q24qter, 17q23, 
18q21qter, Xq21.3q26
171 pT2bN0 5 hypo 8 4 10q26, 18p. -19, 22, Y 1p31, 2p12p13, 2q11q34, 
4q22q26, 5q22, 6q11q23, 
14q22q24, X
175 pT2bN0 8 11 4 13q14 -
183 pT3aN0 6 19 4 1p36,9q34 -
187 pT2bN0 8 chrom8 1 3 16, 17p, 18p, 19, 21, 22, Y 1, 2, 3q13qter, 4q, 5q14q33.1, 
6q16q23, 7p, 7q22q33, 8q, 
11q14.3qter, 12q14qter, 
13q21qter, 14q24q31, 15q, 
Xq22qter
189 pT2bN0 7 none 0 4 3p25p26, 10q26, Xq22qter, Yq -
191 pT2bN0 7 0 3 4q31, 5q31q35, 9q33, 12p12 -
205 pT3aN0 7 5 1 18p, 19, 22, Y 2q31q33, 6q22.3q23, 10q21q22, 
Xp11.1p11.4, Xq
209 pT3aN0 7 both 8 4 1p36, 8p, 16, 17, 18p, 19, 20, 22, 
Y
1q31q32.1, 2q11.1q34, 3, 
4q21.1qter, 5q14q31, 6q11q23, 
7q21q34, 8q, 9, 11q14q22, 
12q15q24, 13q14qter, 18q
213 pT2aN0 7 8 4 8q24.2qter, 14q32, 16, 17, 18p, 
22, Y
-
215 pT3aN0 7 9 4 19q13, 22q13,Y 3q24q26, 5q12, 8p12, 17, 18, 
Xp11p21, X21q24
217 pT2bN0 8 5 4 18p13, Y 2q33q35, 
4q13q28,5q21q31,8q21,8q24,12q
13, 12q21q23, Xq13q25
219 pT4N1 7 both 21 4 5q34qter, 8p22pter, 19, Yq 1p22p31.3, 4q21q22, 4q31.1, 
5q13, 6q24q26, 7q, 8q21q24, 
10q21, 11q14q22, 20q13, 
Xq13q22
225 pT3bN0 6 4 4 4q28, 8q24qter, Yq -
227 pT2aN1 7 3 4 22q13 3q11q21
232 pT2bN1 7 both 13 4 8p22pter -
245 pT3aN0 7 4 3 17p13, 18p 1p31
247 pT3bN1 7 chrom8 3 3 8p21pter, 9q21, 22, Y Xq12
253 pT3aN1 7 1 4 1p36, 2q33q37, 6p21.3p25, 8p21, 
14q31q32, Y
-
256 pT3bN0 7 1 4 2p2p21, 6q, 15q26,16p, 18,X -
The numbers of the tumors used in the microarray analysis are in bold type, as are hypomethylation values considered significantly elevated (< 4%) and typical chromosome 8 
aberrations. All cancers were M0 at the time of prostatectomy. No. hypermethylated genes indicates hypermethylation of APC, GSTP1, RARB2, and RASSF1A. LINE-1 
hypomethylation was determined by Southern blot analysis. Chromosomal dosage changes were determined by comparative genomic hybridization.
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Bioinformatic analysis of microarray expression data Figure 1
Bioinformatic analysis of microarray expression data. A: The distributions of the raw p-values of all genes for the main 
effects hypomethylation of LINE-1 retrotransposons (hypo), alteration of chromosome 8 (chrom8) and for the interaction effect (hypo 
AND chrom8). In each graph the numbers of genes with p-values in the indicated ranges (in increments of 0.02) are shown. 
The uniform distributions of the p-values for the two main single effects indicate that not more genes are declared significant 
than expected at random, whereas for the interaction effect a skewed distribution is observed, i.e. significantly small p-values 
are assigned to a large number of genes. B: The subgraph induced by the top 15 GO terms identified by the classic algorithm 
for scoring GO terms for enrichment. In this graph, nodes represent GO terms and edges represent parent-child relationships, 
i.e. an arrow from node A to node B indicates that the genes in B are a subset of the genes in A. Black arrows indicate is-a rela-
tionships and red arrows part-of relationships, as defined in the Gene Ontology nomenclature. In general, GO terms are rep-
resented by ellipses with the corresponding GO IDs plotted inside. GO IDs surrounded by boxes instead of ellipses indicate 
the 10 most significant GO terms as identified by enrichment analysis. Color represents the relative significance of enrichment, 
ranging from dark red (most significant) to light yellow (least significant). Interesting areas in the GO graph defined by signifi-
cant related GO terms are highlighted by different underlying colors (e.g. red for immune response). C: The subgraph induced 
by the top 15 GO terms identified by the weight algorithm for scoring GO terms for enrichment. For a detailed description see 
Fig. 1B. Circles instead of ellipses indicate GO terms that are found significant by the classic algorithm but not by the weight 
algorithm. see Additional file 3 for a listing of all GO groups in Fig. 1B and 1C
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Box plot representation of microarray analysis results for selected genes Figure 2
Box plot representation of microarray analysis results for selected genes. A: HOXB13; B: BCCIPA; C: HMG20B; D: 
GADD45A; E: MX1; F: MX2; G: CCL5; H: IFNB1; I: IRF3; J: STAT3; K: TLR2; L: TLR3; M: EPB41L3; N: EPB41L4B; O: LAMA2; P: 
SPON2; Q: FBLN1. In each graph, the expression values (log-scale) for the respective genes are depicted for the cancers with 
neither hypomethylation of LINE-1 retrotransposons nor alteration of chromosome 8 (null), hypomethylation only (hypo), 
alteration of chromosome 8 only (chrom8) and both alterations (chrom8 AND hypo). The p-values refer to the result of the 
interaction analysis (see Methods for details).
ABC
D
G
J
M
P
E F
HI
KL
N O
QMolecular Cancer 2007, 6:14 http://www.molecular-cancer.com/content/6/1/14
Page 8 of 16
(page number not for citation purposes)
Box plot comparison of expression of selected genes in prostate cancer vs. benign tissues by real-time quantiative RT-PCR Figure 3
Box plot comparison of expression of selected genes in prostate cancer vs. benign tissues by real-time quantia-
tive RT-PCR. A: HPN; B: HOXB13; C: BCCIP; D: GADD45A; E: MX1; F;TLR3; G: EPB41L3; H: EPB41L4B; I: FBLN1. Expression 
values were determined for each sample in duplicate with < 10% variation. They are indicated relative to the reference gene 
TBP determined in the same fashion. T: cancer samples (n = 47), N: benign tissue samples (n = 13); p-values according to Mann-
Whitney tests.
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Like Hepsin, HOXB13 expression was overall significantly
elevated in cancer tissue (Figure 3B), although the
increase was highly variable. This variation was obviously
related to the presence of chromosome 8 alterations and
LINE-1 hypomethylation (Figure 2A). No other classical
homeobox gene was significant, including the closest
HOXB13  paralogs,  HOXC13  and  HOXD13  (data not
shown). The upregulation of HOXB13, but also its varia-
bility are in keeping with previous studies [17,19].
In contrast, BCCIP  was identified as significant (p =
0.0036) in the interaction analysis, with maximum
expression in the 'both' group (Figure 2B), but its expres-
sion did not differ significantly between cancer and non-
cancerous tissues overall (Figure 3C). BCCIP interacts
with BRCA2. Comparisons of BRCA1, BRCA2, and BARD1
did not yield differences (data not shown), but another
gene interacting with BRCA2, HMG20B, was significant in
the interaction analysis (Figure 2C). Altered expression of
HMG20B has previously been reported in prostate cancer
[18].
GADD45A, which is also induced by BRCA-dependent
pathways, was significantly decreased in prostate cancers
compared to noncancerous tissues (Figure 3D), with the
lowest levels in 'both' cancers (Figure 2D). Expression of
GADD45B or GADD45G was not significantly different
between the tumor groups.
Several genes related to interferon signaling were down-
regulated in the 'both' cancers, most significantly, the pro-
totypic type I interferon response gene MX1 (also named
MXA) (Figure 2E). MX2 (MXB) behaved similarly (Figure
2F). MX1 was also downregulated in cancer tissues overall
(Figure 3E). A significant decrease in the 'both' group was
also observed for CCL5 encoding a chemokine enhancing
interferon responses (Figure 2G). Expression of IFNB1
(encoding IFNβ), but not of IFNG or IFNA genes, was sig-
nificantly lowered according to the interaction analysis
(Figure 2H), and so was accordingly IRF3  (Figure 2I)
encoding a major transcriptional activator of IFNB1.
Another important transcription factor for type I interfer-
ons, STAT3, showed minor decreases (Figure 2J). Interest-
ingly, selected TLRs were downregulated in 'both' cancers,
especially TLR2 (Figure 2K) and TLR3 (Figure 2L). TLR3
expression was decreased in many, but not all prostate
cancers compared to normal tissues (Figure 3F).
The expression differences in immune-response genes
might potentially be due to altered proportions of innate
immune cells in the different tumor groups. We therefore
analyzed, whether several typical marker genes of NK
cells, mast cells, macrophages, dendritic cells, and granu-
locytes were differentially expressed in the 'both' cancers
[see Additional File 2]. Only a single marker, ITGAM
(more commonly known as MAC-1) showed a significant,
but small difference between the groups. From this analy-
sis, the differences in the proportions of innate immune
cells between the tumor groups appear to be small and
cannot account for the overall observed expression differ-
ences.
Expression of cytoskeleton and extracellular matrix genes
Since the classic  algorithm for detecting enriched GO
terms treats each GO term independently, related biolog-
ical terms often appear simultaneously among the top
scoring significant GO terms. In the more sophisticated
weight algorithm, genes annotated to a GO term receive
weights based on the significance of neighboring GO
terms (see Methods). This approach identifies local
dependencies between related GO terms and highlights
those terms that receive a more significant enrichment
score than all their neighbors in the GO graph. Upon
application of the weight algorithm the most significant
GO terms are spread over additional areas in the GO
graph (compare Figure 1B and 1C), identifying a larger
variety of biological processes (Table 2), in addition to
those related to immune response. Most significantly, the
weight algorithm highlights another set of GO groups con-
cerning the interacting processes of cortical actin cytoskel-
etal organization and cell adhesion (areas 3. and 7. in
Figure 1C). In fact, the significance of GO groups 'regula-
tion of embryonic development' and 'positive regulation
of signal transduction' (areas 6. and 8. in Figure 1C) also
derives predominantly from genes related to cell adhesion
[see Additional file 1].
The conspicuous GO group #30865 comprises mostly
genes encoding band 4.1 proteins, officially termed
EPB41L. Most family members were down-regulated in
the 'both' cancers, especially EPB41L3 (Figure 2M) encod-
ing 4.1B. Its expression was highly significantly downreg-
ulated in all prostate cancers compared to normal tissues
(Figure 3G). In contrast, a more distant paralog,
EPB41L4B encoding EHM2, was strongly upregulated in
the 'both' group (Figure 2N), and in cancers overall (Figure
3H). Expression of EPB41L3  and  EPB41L4B  correlated
inversely with each other (Pearson -0.574, p < 0.0001).
A related group of genes identified by interaction analysis
encodes components of basement membranes and extra-
cellular matrix. Genes encoding laminin subunits (Figure
2O) and spondins (Figure 2P) have previously been iden-
tified as differentially expressed in prostate cancer [14-
17,19]. In addition, we observed FBLN1  encoding the
basement membrane component Fibulin-1 to be strongly
downregulated in 'both' cancers (Figure 2Q), and in can-
cers overall (Figure 3I).Molecular Cancer 2007, 6:14 http://www.molecular-cancer.com/content/6/1/14
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In addition to GO groups related to immune response and
cell adhesion or whose significance derives from expres-
sion differences in genes belong to these larger categories,
interaction analysis by the weight algorithm revealed sev-
eral others (Figure 1C, Table 2), which were not investi-
gated further here. Interestingly, many genes significant in
these groups have previously been implicated in prostate
cancer. For instance, GO group #43122 contains genes
related to NFκB regulation. Constitutive activation of
NFκB is widespread in prostate cancer and likely associ-
ated with progression (reviewed in [20]). Increased activ-
ity of Gα proteins and PKA (GO #9187) is thought to
enhance androgen receptor activity [21] and influence
hedgehog signaling [22]. Expression of monoamine oxi-
dase responsible for the significance of GO group #42135
correlates closely with Gleason score and prostate cancer
prognosis [23]. Phosphatic acid phosphatase 2a responsi-
ble for the significance of the GO group #8354 was previ-
ously identified in a screen for genes differentially
expressed in prostate cancer [24].
For all genes in Fig. 3 the relationship of expression to
tumor stage, lymph node involvement, Gleason score,
and biochemical recurrence was investigated. After adjust-
ment for multiple testing, significant associations were
obtained for two relations. HPN expression was associ-
ated with Gleason score, and TLR3 expression was associ-
ated with recurrence. As for several other genes, altered
expression of TLR3 tended furthermore to be associated
with increased tumor stage.
DNA methylation analysis of novel prostate cancer genes
Several genes conspicuous in the present study are subject
to DNA hypermethylation in other cancers, prominently
EPB41L3 [25,26] and GADD45A [27].
Downregulation of EPB41L3  in other carcinomas is
caused by allelic loss at 18p11.3 or promoter hypermeth-
ylation [25,26]. In the present study, eleven cancers
showed loss, but only 4 gains at chromosome 18p (Table
1). Bisulfite sequencing revealed EPB41L3  promoter
hypermethylation in prostate cancer tissues and cell lines,
low methylation in benign prostate tissues and none in
leukocytes (Figure 4A). Methylation-specific PCR (Figure
4B) detected EPB41L3 hypermethylation in 79% of the
cancer tissues. In prostate carcinoma cell lines, with the
exception of PC3, EPB41L3 expression was undetectable
even by highly sensitive real-time RT-PCR. Accordingly,
the EPB41L3 promoter was strongly methylated in all cell
lines, but less so in PC3 (Figure 4A). Combined treatment
with a DNA methyltransferase inhibitor, 5-aza-dC, and a
histone deacetylase inhibitor, SAHA, induced EPB41L3
expression to detectable levels in Du145 and 22Rv1, while
expression in PC3 and LNCaP remained unchanged (data
Table 2: Top 20 significant GO groups in interaction analysis, sorted according to the weight algorithm
Rank (weight) GO ID GO Term definition Annotated
number of genes
Significant
number of genes
Expected
number of genes
Rank (classic) p-value (classic) p-value (weight)
1 GO:0006955 immune response 1241 57 26.05 2 1.50E-08 3.30E-05
2 GO:0009607 response to biotic stimulus 1409 63 29.58 1 6.40E-09 5.30E-05
3 GO:0030865 cortical cytoskeleton 
organization and biogenesis
22 5 0.46 8 7.80E-05 7.80E-05
4 GO:0001766 lipid raft polarization 2 2 0.04 11 0.00044 0.00044
5 GO:0006956 complement activation 49 6 1.03 15 0.00054 0.00054
6 GO:0007155 cell adhesion 972 36 20.40 16 0.00067 0.00076
7 GO:0009967 positive regulation of signal 
transduction
176 11 3.69 22 0.00125 0.00125
8 GO:0009611 response to wounding 589 25 12.36 17 0.00070 0.00137
9 GO:0045995 regulation of embryonic 
development
12 3 0.25 24 0.00175 0.00175
10 GO:0042135 neurotransmitter 
catabolism
15 3 0.31 28 0.00346 0.00346
11 GO:0043122 regulation of I-kappaB 
kinase/NF-kappaB cascade
149 9 3.13 29 0.00425 0.00425
12 GO:0006952 defense response 1354 60 28.42 3 2.20E-08 0.00445
13 GO:0009190 cyclic nucleotide 
biosynthesis
33 4 0.69 33 0.00483 0.00483
14 GO:0050678 regulation of epithelial cell 
proliferation
17 3 0.36 34 0.00501 0.00501
15 GO:0008354 germ cell migration 7 2 0.15 39 0.00861 0.00861
16 GO:0009613 response to pest, pathogen 
or parasite
776 34 16.29 7 4.20E-05 0.01258
17 GO:0016064 humoral defense 
mechanism (sensu 
Vertebrata)
165 10 3.46 25 0.00258 0.01310
18 GO:0006024 glycosaminoglycan 
biosynthesis
24 3 0.50 46 0.01339 0.01339
19 GO:0050672 negative regulation of 
lymphocyte proliferation
9 2 0.19 47 0.01435 0.01435
20 GO:0008037 cell recognition 28 3 0.59 58 0.02038 0.02038Molecular Cancer 2007, 6:14 http://www.molecular-cancer.com/content/6/1/14
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not shown). In the same experiment, 5-aza-dC strongly
induced  CTCFL  and SAHA induced CDKN1A/p21CIP1
expression, as described ([11]).
Treatment with a combination of 5-aza-dC and SAHA
increased expression of GADD45A in two prostate cancer
cell lines, PC3 and DU145. Induction was slight in 22Rv1,
and the inhibitors were inefficacious in LNCaP (Figure
4C). In spite of the response to 5-aza-dC, bisulfite
sequencing revealed the GADD45A  promoter to be
unmethylated in prostate cancer cell lines and prostate
cancer tissues with low expression (Figure 4D).
Discussion
The starting point of the present investigation was our pre-
vious observation that chromosome 8 alterations and
LINE-1 hypomethylation concurred in many prostate can-
cers [8]. Such a relationship could be mechanistic in the
sense that one alteration causes the other. For instance,
chromosome 1 alterations may sometimes be a conse-
quence of hypomethylation of CpG-rich satellites
enriched in its juxtacentromeric heterochromatin [28].
Clearly, the fact that the highly significant association was
not replicated in the present study makes mechanistic
relationships of this kind unlikely. The major difference in
the former study was a high proportion of metastatic and
recurrent cancers, which exhibited LINE-1 hypomethyla-
DNA methylation analysis of EPB41L3 and GADD45A Figure 4
DNA methylation analysis of EPB41L3 and GADD45A. A: Bisulfite sequencing of the EPB41L3 promoter in selected cell 
lines and prostate tissue samples. Du145, PC3, 22Rv1, and LNCaP: prostate cancer cell lines. T: tumor tissues; N: benign tis-
sues, UP: normal urothelial cells. B: Examples of Methylation-specific PCR for EPB41L3. M: primers specific for methylated pro-
moter sequence, U: primers specific for unmethylated promoter sequence. T: prostate carcinoma tissue, N: benign prostate 
tissue, Bl: blood leukocyte DNA as unmethylated control, Du: Du145 DNA as methylated control. C: Effect of 5-aza-dC and 
SAHA on GADD45A expression. For each cell line from left to right: untreated (white bars), 5-aza-dC (horizontal stripes), 
SAHA (vertical stripes), 5-aza-dC + SAHA (black bars). D: Bisulfite sequencing of GADD45A in selected cell lines and prostate 
tissue samples. Du145, PC3, 22Rv1, and LNCaP: prostate cancer cell lines. T: tumor tissues; N: benign tissues
A C
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tion regularly and chromosome 8 alterations often. There-
fore, a likely explanation for the discrepancy is that LINE-
1 hypomethylation and chromosome 8 alterations both
contribute to prostate cancer progression, but are brought
about by independent causes.
The fact that they concur in advanced cancers suggests a
synergism between the two factors that could be exerted in
two ways. Each alteration could target independent bio-
logical processes contributing to tumor progression, e.g.
one might promote cell proliferation, while the other
blocks apoptosis. Alternatively, both factors could target
the same process(es). The expression profiling experiment
in the present study was designed to distinguish between
these alternatives and to identify relevant biological proc-
esses. The results clearly indicate that the two alterations
act upon the same processes. Very few genes were signifi-
cantly different between the tumors with or without LINE-
1 hypomethylation or between those with or without
chromosome 8 alterations, whereas interaction analysis
identified several clearly circumscribed biological proc-
esses. One prominent process can be roughly categorized
as suppression of immune responses, a second one as
altered cytoskeletal organization and cell adhesion. Both
processes are considered generally important in carcino-
genesis, especially during tumor progression. Of note,
these processes were identified by the interaction analysis
as particularly important in the group of cancers with
both alterations. The analysis of individual genes by
quantitative real-time PCR revealed that many (e.g. MX1,
EPB41L3), but not all (notably BCCIP and TLR3) of the
genes significant in the interaction analysis were also over-
expressed generally in prostate cancers compared to
benign tissues.
More specifically, most individual genes differentially
expressed in the immune-response GO groups relate to
the activation of innate immune responses following viral
infection. A key step in this response is the production of
type I interferons by infected cells. These exert antiprolif-
erative effects themselves and initiate adaptive immune
responses. Antiproliferative and proapoptotic factors
from T-cells, including IFNγ, then help to eliminate
infected cells. The same sequence is thought to be
involved in immunosurveillance against tumors caused
by viruses and other carcinogens [29]. In particular, loss of
responsiveness to IFNγ has previously been linked to pros-
tate cancer progression [30,31]. This result is strengthened
by our finding that genes associated with interferon
responses are down-regulated in prostate cancer com-
pared to normal tissue overall and even more so in a sub-
group of cancers harboring molecular alterations typical
of advanced stage tumors. Importantly, however, the
genes identified as downregulated in our analysis include
several that are involved in the earlier phase mediated by
type I interferons, especially the prototypic type I inter-
feron response genes MX1 and MX2. Of note, MX1 has a
direct antiproliferative effect [32], as does GADD45α [33].
IFNB1 itself and IRF3 encoding a key transcription factor
for its synthesis appeared downregulated in the group of
prostate cancers with both alterations, too. In addition,
expression of certain toll-like receptors including TLR2
and TLR3 that recognize 'alien' structures was diminished,
at least in this subgroup. Downregulation of TLR3, which
detects dsRNA of viral origin and aberrantly methylated
endogenous RNAs [34] is apparent from a previous pros-
tate cancer microarray study, but not was not followed up
there [15]. Our findings thus suggest that the immune
response to some prostate cancers may fail at at an early
step because the cancers are not recognized. The finding
that TLR3 down-regulation occurred in a subset of cancers
and was associated with recurrence may mean that some
cancers are more successful than others in escaping detec-
tion by the immune system.
Our findings are particularly intriguing when considered
together with current knowledge on hereditary prostate
cancer genes. The best characterized HPC1 gene encodes
RNaseL, a protein involved in response to dsRNA pro-
duced during viral infections or certain other aberrant
RNAs [35]. Another hereditary prostate cancer gene candi-
date is MSR1 at 8p23 likewise involved in innate immune
responses [1]. Polymorphisms in TLR  genes have also
been implicated as predisposition factors [36,37]. Intrigu-
ingly, two genes (BCCIP, HMG20B) appeared in our anal-
ysis that interact with BRCA2, another, albeit weaker
candidate for a hereditary prostate cancer gene [1].
GADD45A  found downregulated in prostate cancers in
our study is a well-established BRCA1 target. BRCA1 and
IFNγ together act upon the RNaseL pathway [38].
The preponderance of immune response genes among
hereditary prostate cancer genes has been interpreted as
indicating a role for an aberrant immune response
towards a viral agent in prostate carcinogenesis [1,35].
Obviously, our data are in line with that interpretation. Of
note, the cancers displaying the most pronounced down-
regulation of immune response-related genes harbored
significant hypomethylation of LINE-1 retrotransposons
and chromosome 8 alterations. Diminished methylation
may facilitate LINE-1 reexpression [39]. LINE-1
hypomethylation in cancer parallels that of HERV endog-
enous retroviruses [39,40] and of ALU (SINE) sequences
[40]. Activation of endogenous retroelements occurs in
response to various types of genotoxic stress and may also
take place during infection by exogenous viruses
(reviewed in [41]). Indeed, processed HERV transcripts
have been observed in prostate cancer [42]. HERV pro-
teins are recognized as autoantigens in cancer and autoim-
mune diseases [41,43]. ALU transcripts influence theMolecular Cancer 2007, 6:14 http://www.molecular-cancer.com/content/6/1/14
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dsRNA-dependent protein kinase PKR, which regulates
RNaseL activation, and TLRs [44]. Conceivably, therefore,
what appears as an aberrant response to an exogenous
viral agent in prostate carcinogenesis might reflect to
some extent the activation of endogenous retroelements.
Interestingly, the recent completion of the chromosome 8
sequence has highlighted an unusual concentration of
genes involved in the regulation of the immune response
on this particular chromosome [45]. Therefore, a specula-
tive interpretation of our findings is that increased expres-
sion of endogenous retroelements in prostate cancer cells
with hypomethylated genomes would contribute to the
activation of immune responses, but is tolerated as a con-
sequence of chromosome 8 alterations. We suggest this as
a working hypothesis for further studies.
Similarly, our study implies that altered expression pat-
terns of cytoskeletal and extracellular matrix proteins in
prostate carcinoma are linked to alterations of chromo-
some 8 and LINE-1 hypomethylation. A novel finding in
this context is the involvement of 4.1 proteins in prostate
cancer. These proteins contain a phosphatidyl inositol
phosphate-binding domain and connect a variety of
transmembrane proteins to the actin cytoskeleton,
thereby organizing cell polarity and motility. The two
members of the family investigated here more closely are
already implicated in other cancers. EPB41L3  was pro-
posed as a potential tumor suppressor in lung cancer [25]
and was shown to be down-regulated by promoter hyper-
methylation and allelic loss in renal cell carcinoma [26].
We report here that hypermethylation of EPB41L3 is also
prevalent in prostate cancer. The 18p losses detected by
CGH in 11/50 cases, could contribute to down-regula-
tion. EHM2 encoded by EPB41L4B was identified as over-
expressed in metastatic melanoma cells [46]. We show
here that its overexpression is common in prostate cancer.
This is the first explicit study on this gene, but our findings
are in line with significant differences in previous micro-
array data [14,15]. Taken together, the results suggest a
shift in the pattern of 4.1 proteins associated with prostate
cancer progression whose biological and clinical implica-
tions deserve further investigation.
Altered expression of Fibulin-1, which interacts with lam-
inins reported to be downregulated in several previous
studies [14-17], was previously reported only in gynaeco-
logical cancers [47,48]. In these cancers, FBLN1 becomes
upregulated during progression. In contrast and therefore
surprisingly, in prostate cancer FBLN1 appears to become
generally downregulated. The decreases in laminin and
Fibulin-1 expression may be related to the dissolution of
the basement membrane in prostate cancer tissues. Like
the 4.1 proteins, Fibulin-1 influences cell motility and
polarity. As overexpression and abnormal localization in
breast cancer can lead to recognition of Fibulin-1 as an
autoantigen [48], its decreased expression in prostate can-
cers may also lower their immunogenicity.
Promoter hypermethylation underlies GADD45A down-
regulation in breast cancer [27]. In prostate cancer altered
methylation at a more distant, but unfortunately unspec-
ified site in the gene has been reported [49]. We found the
actual promoter unmethylated in prostate cancer tissues
and cell lines. Induction of GADD45A by SAHA treatment
in prostate cancer cell lines could mean that downregula-
tion is associated with histone deacetylation and altered
chromatin structure. The additive effect of 5-aza-dC treat-
ment might reflect the methylation at the distant site [49].
Conclusion
LINE-1 hypomethylation and chromosome 8 alterations
are commonly associated in highly advanced prostate can-
cers. The present study suggests that both alterations do
not cause each other. Rather, they appear to act as con-
verging and even synergistic factors contributing to pros-
tate cancer progression. Interaction analysis identified
suppression of innate immune responses and cytoskeletal
and extracellular matrix changes as common targets. This
implies that candidate tumor genes on chromosome 8 as
well as DNA hypomethylation should be considered for
their influence on these processes in prostate cancer.
Intriguingly, many hereditary prostate cancers genes are
also involved in regulation of innate immune responses.
The data stress the importance of altered cell adhesion and
cytoskeletal organization in prostate cancer and specifi-
cally implicate changes in 4.1 protein expression in this
process. The 4.1 protein encoding genes and several oth-
ers newly identified here ought to be investigated for their
usefulness in prostate cancer detection and classification
through expression or methylation analyses.
Methods
Tissue samples
From a previous study of DNA methylation alterations in
a series of 113 prostate carcinomas [9], a subset of 50
specimens (Table 1) was selected according to DNA avail-
ability, RNA quality and complete follow-up (median
period 62 months). Cases with distant metastases at the
time of surgery were excluded. Twelve cases had lymph
node metastases. Benign tissues were taken from distant
locations of cancer-carrying prostates as described [9]. The
study was approved by the HHU medical faculty ethics
committee.
Cell lines
The prostate carcinoma cell lines LNCaP, 22RV1, PC3,
and DU145 were cultured and treated with epigenetic
inhibitors, 5-aza-2'-deoxycytidine (5-aza-dC; Sigma,
Taufkirchen, Germany), suberoylanilide hydroxamic acid
(SAHA, Biomol, Hamburg, Germany) as described [11].Molecular Cancer 2007, 6:14 http://www.molecular-cancer.com/content/6/1/14
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5-aza-dC was supplied at 2 μM every 24 h for 3 days and
suberoylanilide hydroxamic acid at 2 μM for 2 days.
DNA and RNA extraction
DNA and RNA were extracted from identical powdered
tissues as described previously [9,11].
Comparative genomic hybridization
CGH was performed as described [12], using the same
aliquots as for DNA methylation analysis.
RNA microarray analysis
High-quality total RNA (5 μg each) was converted to dou-
ble-stranded cDNA before in vitro transcription with bioti-
nylated dNTPs using the GeneChip®  Expression 3'
Amplification One-Cycle Target Labeling Kit (Affymetrix,
Santa Clara, USA). The resulting biotinylated cRNA was
fragmented and hybridized to HG-U133A (Affymetrix)
microarrays according to the manufacturer's specifica-
tions. After hybridization, the microarrays were washed,
stained with streptavidin/phycoerythrin conjugate and
biotinylated antibody, and scanned according to the man-
ufacturer's recommendations using an Affymetrix Gene-
Chip®  Scanner 3000. Images were processed using
GeneChip®  Operating Software (GCOS, Version 1.3,
Affymetrix) and total intensity normalization was applied
by normalizing all arrays to an average signal level of 500
counts.
Bioinformatic analysis of microarray data
Interaction analysis
For every gene separately, a multivariate linear model for
predicting logarithmic gene expression was estimated.
Two main effects for alteration of chromosome 8 and for
hypomethylation of LINE-1 retrotransposons and an
interaction effect for joint occurrence of these two factors
were included in the model. Significance values for every
gene and for the three effects, respectively, were obtained
by applying the function lm for fitting linear models as
implemented in the R programming language R [50].
GO group scoring
Two methods for scoring the significance of enrichment of
a list of differentially expressed genes with genes belong-
ing to a Gene Ontology (GO) group were applied, namely
the classic and the weight algorithm [13]. In both algo-
rithms, genes are first ranked according to a score that
quantifies the amount of differential expression. Corre-
sponding p-values are then adjusted for multiple testing
according to the false discovery rate (fdr) method. All genes
with adjusted p-values p < 0.05 are included in the list of
significant genes. The significance of a GO term is then
obtained by comparing the observed number of genes in
the respective GO group that are members of this list with
the expected number calculated in a model that assumes
independence between the GO group and the list of sig-
nificant genes. In the classic algorithm, this comparison is
based on Fisher's exact test which is applied for each GO
term independently. Due to the graph topology of the
Gene Ontology, pairs of terms with parent-child relation-
ships automatically receive similar p-values and thus
appear simultaneously among the most significant GO
terms. In the weight algorithm, genes annotated to a GO
term receive weights based on the significance of neigh-
boring GO terms [13]. This approach identifies local
dependencies between related GO terms and highlights
those terms that receive a more significant score than all
their neighbors. The algorithms for GO group scoring
were implemented in the R programming language [50].
The results were obtained using R version 2.3.0 and the
libraries provided by the Bioconductor project, version
1.8 (released on April 27th, 2006).
Quantitative RT-PCR
Quantitative real-time RT-PCR was performed using RNA
from the identical tissue specimens on an ABI 7900
instrument using commercially available primers and
probes specific for the respective mRNAs (Applied Biosys-
tems, Weiterstadt, Germany). Each run was standardized
using a dilution series of a strongly expressing cell line or
normal tissue. Experimental variation for each sample was
below 10%. All results were expressed relative to TBP used
as a reference gene.
DNA methylation analysis
Bisulfite sequencing DNA methylation analysis was per-
formed as described [9,11] using the following novel
primers for EPB41L3  DAL1fwd 5'-GTAATAGGGGG(T/
C)GGGGGGAATAG-3', DAL1rev 5'-AACCCCCTC(A/
G)CAATCCCCCACTC-3' for GADD45A: GADD45Afwd
5'-TTAGTGGTTGGTAGGTAGTGGTT-3', GADD45Arev 5'-
CCTCCAAAATCATATTACAAACTAC-3'. Methylation-spe-
cific PCR was performed as described [9] using the novel
primer pairs for EPB41L3 DAL1US 5'-TTTGTGTATTGTT-
GTTGAGGAGTG-3' and DAL1UAS 5'-CACAATC-
CCCCACTCCAAAAAACA-3' to detect unmethylated
sequences or DAL1MS 5'-TTGCGTATCGTCGTCGTC-
GAGGACG-3' and DAL1MAS 5'-CGCAATCCCCCACTC-
CGAAAAACG-3' to detect methylated sequences at 61°C
and 64°C annealing temperature, respectively.
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